Function Therapeutics, Inc.
Milwaukee, WI · Biotech · Private
Parmodulins, a novel class of small-molecule allosteric modulators of protease-activated receptor 1 (PAR1) for treating sickle cell disease
function-therapeutics.com →- Grants
- $2.0M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1) | $274,710 | |
| Federal grant | Department of Health and Human Services · Phase I · Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease | $299,790 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors of Thromboinflammation for Acute Kidney Injury | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule PAR1 Ligands for the Treatment of MASH | $463,714 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibitors of Thromboinflammation for Acute Kidney Injury | $88,907 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Small Molecule PAR1 Ligands for the Treatment of MASH | $39,740 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain | $499,863 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1782 | BIOMORPH TECHNOLOGIES LLC | — | — |
| 1783 | LIPO-IMMUNO TECH, LLC | — | — |
| 1784 | Sisu Pharma, Inc. | — | $1.7M |
| 1785 | Function Therapeutics, Inc. | — | — |
| 1786 | SmartLife, Inc. | — | $225K |
| 1787 | Evofem Biosciences, Inc. | — | $86M |
| 1788 | AGILE THERAPEUTICS INC | — | $81M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.